company background image
YMTX

Yumanity Therapeutics NasdaqCM:YMTX Stock Report

Last Price

US$1.66

Market Cap

US$18.0m

7D

1.8%

1Y

-82.9%

Updated

11 Aug, 2022

Data

Company Financials
YMTX fundamental analysis
Snowflake Score
Valuation2/6
Future Growth0/6
Past Performance0/6
Financial Health3/6
Dividends0/6

YMTX Stock Overview

Yumanity Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the research and development of treatments for neurodegenerative diseases caused by protein misfolding.

Yumanity Therapeutics, Inc. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Yumanity Therapeutics
Historical stock prices
Current Share PriceUS$1.66
52 Week HighUS$13.90
52 Week LowUS$0.95
Beta0
1 Month Change-5.68%
3 Month Change38.35%
1 Year Change-82.85%
3 Year Changen/a
5 Year Changen/a
Change since IPO-92.49%

Recent News & Updates

Shareholder Returns

YMTXUS BiotechsUS Market
7D1.8%1.2%1.3%
1Y-82.9%-23.0%-11.7%

Return vs Industry: YMTX underperformed the US Biotechs industry which returned -22.1% over the past year.

Return vs Market: YMTX underperformed the US Market which returned -11.6% over the past year.

Price Volatility

Is YMTX's price volatile compared to industry and market?
YMTX volatility
YMTX Average Weekly Movement18.1%
Biotechs Industry Average Movement12.5%
Market Average Movement7.8%
10% most volatile stocks in US Market16.9%
10% least volatile stocks in US Market3.2%

Stable Share Price: YMTX is more volatile than 90% of US stocks over the past 3 months, typically moving +/- 18% a week.

Volatility Over Time: YMTX's weekly volatility (18%) has been stable over the past year, but is still higher than 75% of US stocks.

About the Company

FoundedEmployeesCEOWebsite
201441Richard Petershttps://www.yumanity.com

Yumanity Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the research and development of treatments for neurodegenerative diseases caused by protein misfolding. The company focuses on discovering disease-modifying therapies to treat neurodegenerative diseases, including Parkinson’s disease, dementia with Lewy bodies, multiple system atrophy, amyotrophic lateral sclerosis, and frontotemporal lobar degeneration. Its lead program is YTX-7739, a novel small molecule that is in Phase I clinical trial for the treatment of Parkinson’s disease and related disorders of a-synuclein.

Yumanity Therapeutics, Inc. Fundamentals Summary

How do Yumanity Therapeutics's earnings and revenue compare to its market cap?
YMTX fundamental statistics
Market CapUS$18.02m
Earnings (TTM)-US$38.59m
Revenue (TTM)US$5.08m

3.5x

P/S Ratio

-0.5x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
YMTX income statement (TTM)
RevenueUS$5.08m
Cost of RevenueUS$18.90m
Gross Profit-US$13.82m
Other ExpensesUS$24.77m
Earnings-US$38.59m

Last Reported Earnings

Jun 30, 2022

Next Earnings Date

n/a

Earnings per share (EPS)-3.55
Gross Margin-272.21%
Net Profit Margin-760.15%
Debt/Equity Ratio7.3%

How did YMTX perform over the long term?

See historical performance and comparison